60 Degrees Pharmaceuticals (SXTP) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
60 Degrees Pharmaceuticals is the larger company by market cap ($3.4 million vs $2.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SXTP | XRTX |
|---|---|---|
| Share price | $0.9654 | $1.41 |
| Market cap | $3.40M | $2.56M |
| 1-day change | -0.73% | -23.78% |
| Forward P/E | — | 1.76 |
| EPS (TTM) | $-5.34 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.62 | $7.05 |
| 52-week low | $0.84 | $1.36 |
| Distance from 52-week high | -88.80% | -80.00% |
| Analyst consensus | none | — |
| Avg. price target upside | +283.26% | — |
| Average volume | 130.52K | 376.30K |
| Shares outstanding | 3.52M | 1.82M |
| Employees | 3 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About 60 Degrees Pharmaceuticals
SXTP stock →60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
SXTP vs XRTX FAQ
Which is bigger, 60 Degrees Pharmaceuticals or XORTX Therapeutics?
60 Degrees Pharmaceuticals (SXTP) is larger, with a market capitalization of $3.40M compared with $2.56M for XORTX Therapeutics (XRTX).
Are 60 Degrees Pharmaceuticals and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.